Navigation Links
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
Date:1/22/2009

of dry eye disease in the first half of 2009. Once this lower strength Xibrom trial is completed, we will make a decision on which product or products in our dry eye franchise to move into Phase III trials, which could start as early as 2010."

ISTA's previous two Phase II trials of ecabet, which were conducted in a controlled environment chamber, demonstrated positive trends in patient's symptoms (OSDI and patient's worst symptom, both trials) and in the signs of corneal staining (one trial) and blink rate (both trials). The Company believes the lack of response to ecabet in symptoms in the most recent trial is not of concern, in part because the OSDI responses to ecabet sodium were strong and predictable in the previous Phase II trials. ISTA believes that given the ability to demonstrate a positive effect on signs in the environment and on symptoms in the controlled environment chamber, there is now a clear path forward to Phase III studies and New Drug Application filing for this product.

Background on ISTA's Recent Phase IIb Study Results

ISTA's Phase IIb trial randomized 144 patients to receive either ecabet sodium or placebo four times per day for 43 days. The object of the study was to investigate ecabet sodium's effects on the objective signs of tear production (Anesthetized and Unanesthetized Schirmer Tests) and tear film quality (TFBUT) and subjective symptoms (OSDI, patient's worst symptom) in patients with dry eye disease when administered under normal environmental conditions.

In the analysis of responders to both ecabet sodium and placebo, results of the Anesthetized Schirmer Test in the Phase IIb study revealed a strong trend for ecabet sodium, which approached statistical significance versus placebo. This result is important because it indicates an effect on basal tear secretion, which is one of the main factors in the etiology of dry eye disease. In addition, the percentage of
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
6. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
7. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
9. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... named the 2013 Life Science Firm of the Year by ... Vanda was honored at the TCM,s 25 th Annual ... Maryland.  The Tech Awards Celebration recognizes the leaders and innovators ... Maryland and the surrounding regions. ...
(Date:5/23/2013)... 2013 Nephros, Inc. (OTC Bulletin Board: ... that develops and sells high performance liquid purification ultrafilters, ... In addition, the concurrent temporary reduction in exercise price ... 17, 2013. Nephros estimates that it will ... offering.   A portion of the proceeds will be used ...
(Date:5/23/2013)... -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a ... intellectual property developed and owned by Hadassah University ... research center, today announced that its portfolio company, ... the Israeli Ministry of Industry and Commerce, Office ... development and advance clinical trials. Cell Cure,s development ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... PORTLAND, Maine , Jan. 18 Putney, Inc., a ... Jean Hoffman , founder and CEO, will present at the ... 2010 in New York, NY . , The ... private companies within the areas of acute care, distribution, healthcare IT, ...
... , ALLEGAN, Mich., Jan. 7 Perrigo Company ... and CEO Joseph C. Papa will present at the 28th ... 10:00 a.m. (PT) at the Westin St. Francis Hotel in ... healthcare supplier that develops, manufactures and distributes OTC and generic ...
Cached Medicine Technology:Putney to Present at the Jefferies 2010 Global Healthcare Services Conference 2
(Date:5/24/2013)... 2013 With Memorial Day Weekend upon us, ... is offering tips to help prevent grill fires throughout ... Association (NFPA) reports that gas grills led to an ... or other solid-fueled grills, meanwhile, caused approximately 1,200 home fires ... Amica Insurance is sharing the following tips from the NFPA ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
(Date:5/24/2013)... Drugs commonly used to treat glaucoma may cause droopy ... vision, according to a new study. The drugs, ... reduce eye pressure, have already been shown to cause ... researchers said, suggesting that the new findings could lead ... be conservative when prescribing these drugs, the researchers added, ...
(Date:5/24/2013)... highly respected Alzheimer,s researchers failed to replicate what appeared ... brain disease when they were published last year in ... online Feb. 9, 2012, suggested that the drug bexarotene ... beta amyloid plaques (Aβ) a pathological hallmark of ... to the authors of the 2012 report, drug treatment ...
(Date:5/24/2013)... York (PRWEB) May 24, 2013 The ... involving Intuitive Surgical Inc.’s da Vinci Surgical System ... court records, a Washington State Court jury ruled in ... in training a surgeon who performed a da Vinci ... The patient’s family had alleged in their lawsuit ...
Breaking Medicine News(10 mins):Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3
... Facial expressions convey strong cues for someone,s emotional ... crucial in social interaction. This ability is known to ... as social anxiety or Korsakoff,s syndrome. New research has ... also characterized by changes in the way the brain ...
... 16 (HealthDay News) -- Many women in the United States ... due to dangerous ingredients, a new study indicates. Pai ... which are banned in the United States because they increase ... U.S. Food and Drug Administration announced a recall of Pai ...
... exercise routine means being able to overcome the obstacles ... the confidence that you can do it, researchers report. ... abilities increase this "situation-specific self-confidence," a quality the researchers ... self-efficacy to every single health behavior you can think ...
... You might want to take a pass on that nightcap, ... hinders the restorative functions of sleep. The findings, from ... in the November print issue of the journal Alcoholism: ... sleep appears linked to a disruption in nervous system function. ...
... , MONDAY, Aug. 15 (HealthDay News) -- ,Just 15 minutes ... by 14 percent and increase your life expectancy by three years, ... do at least 150 minutes, or a total of 1.5 hours, ... that doing even half that -- 15 minutes daily is about ...
... public standards incorporating new tests for impurities as well ... of over-the-counter (OTC) ingredients and products will be key ... co-sponsored by the U.S. Food & Drug Administration (FDA) ... addition to providing updates on new standards for acetaminophen ...
Cached Medicine News:Health News:Reduced recognition of fear and sadness in post-traumatic stress disorder 2Health News:U.S. Women Using Dangerous Weight-Loss Pill 2 Years After Recall 2Health News:Want to keep your exercise resolutions? New research offers pointers 2Health News:Want to keep your exercise resolutions? New research offers pointers 3Health News:More Evidence That Alcohol Hinders Good Sleep 2Health News:A Little Exercise Goes a Long Way to Cut Disease, Death Risk 2Health News:FDA-USP workshop to preview updated OTC standards 2Health News:FDA-USP workshop to preview updated OTC standards 3
... Mixevac® III represents the latest in advanced ... mixes all types of bone cement safely and ... system ensures the blades scrape the bowl whether ... superior mix. , ,The new bowl ...
... Tobramycin is the original Simplex™ ... the addition of 1g of ... formula, surgeons can expect the ... P Bone Cement, while ensuring ...
... Blood Flow Analyzer is a fast, clinically ... diagnosis of low and normal-tension glaucoma., ,The ... fast, clinically proven measurement that improves detection ... the management of glaucoma, and detection of ...
... Insertion/Removal ,The Mackool Cataract Support ... to the lens capsule and enclosed ... of zonular status. Insertion is ... retractors), and removal is accomplished in ...
Medicine Products: